Background: The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society and shows a high dementia prevalence rate of up to 40%. Only a few studies have investigated protective factors for cognitive impairment in the oldest-old. The EMIF-AD 90+ Study aims to identify factors associated with resilience to cognitive impairment in the oldest-old. In this paper we reviewed previous studies on cognitive resilience in the oldest-old and described the design of the EMIF-AD 90+ Study. Methods: The EMIF-AD 90+ Study aimed to enroll 80 cognitively normal subjects and 40 subjects with cognitive impairment aged 90 years or older. Cognitive impairment was operationalized as amnestic mild cognitive impairment (aMCI), or possible or probable Alzheimer's Disease (AD). The study was part of the European Medical Information Framework for AD (EMIF-AD) and was conducted at the Amsterdam University Medical Centers (UMC) and at the University of Manchester. We will test whether cognitive resilience is associated with cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity, genetic risk factors, hallmarks of ageing, and markers of neurodegeneration. Markers of neurodegeneration included an amyloid positron emission tomography, amyloid β and tau in cerebrospinal fluid/blood and neurophysiological measures. Discussion: The EMIF-AD 90+ Study will extend our knowledge on resilience to cognitive impairment in the oldest-old by extensive phenotyping of the subjects and the measurement of a wide range of potential protective factors, hallmarks of aging and markers of neurodegeneration. Trial registration: Nederlands Trial Register NTR5867. Registered 20 May 2016.
Background

Introduction
The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society [1] . Worldwide, the number of oldest-old subjects is expected to increase to 71.2 million in 2050, a 5-fold increase of the current oldest-old population [2, 3] . The oldest-old have a high risk of developing dementia with a prevalence up to 40% [4] . The increasing number of oldest-old subjects with dementia will have major clinical and financial consequences for patients, their families and society as a whole [5] .
Still a considerable number of subjects remain cognitively normal at high age, indicating the presence of protective factors for cognitive impairment in these subjects. Identification of these protective factors is crucial and will have implications for preventive strategies. In addition, identifying the neurodegenerative markers associated with cognitive impairment in the oldest-old, will enhance our understanding of the underlying pathophysiology in this specific age group.
The EMIF-AD 90+ study was set-up to investigate protective factors for cognitive impairment in the oldest-old. We will first provide an overview of the current status of research on this topic and then present the study outline of the EMIF-AD 90+ study.
Review on studies on cognitive impairment in the oldest-old
We searched for studies focusing on protective factors for cognitive impairment in nonagenarians, which gave us two results: The 90+ Study in the USA and the Danish Birth Cohort Studies [6, 7] . Broadening the search to studies that started inclusion from the age of 85 years or focused on successful aging resulted in eight more studies: the H85 Gothenburg study, Leiden 85-plus Study, Newcastle 85+ Study, NonaSantfeliu study, Octabaix study, Project of Longevity and Aging in Dujangyan (PLAD), Umeå study and Vantaa 85+ Study [8] [9] [10] [11] [12] [13] [14] [15] . Table 1 shows the design characteristics of these ten studies.
Protective factors for cognitive impairment in the oldest-old Table 2 summarizes the findings on the protective factors for cognitive impairment or dementia of the ten studies. A high level of education was found to be protective against dementia in the oldest-old and one study indicated that high cognitive activity, examined by looking at the time spend on reading, around age 90 years was related to resilience to dementia [4, [16] [17] [18] . The influence of vascular comorbidities on cognition has been studied quite extensively in this age group. Most studies did not find an association between cholesterol levels and cognition in the oldest-old [15, 17, [19] [20] [21] [22] . Hypertension has mostly been found to be protective in the oldest-old, especially when hypertension is diagnosed after the age of 80 years [17, 19, [23] [24] [25] [26] [27] . This is in contrast to studies that have shown a higher dementia risk in the presence of midlife hypertension [28] . In addition, although midlife diabetes mellitus has been related to dementia in younger subjects [29] , the influence of diabetes mellitus on cognition might be less evident in the oldest-old [11, 30, 31] . The protective effect related to the absence of stroke seemed to persist in the oldest-old [18, 32] and one study on atrial fibrillation and dementia did not find an association [32] . The absence of depressive symptoms seemed to be associated with resilience to cognitive impairment, which is consistent with findings in younger subjects [14, 33, 34] . One study related sleep quality to cognition and reported a higher sleep quality in subjects without cognitive impairment, which is in line with results in younger subjects [35, 36] . With regard to the sensory system, visual and auditory impairments have been associated with worse cognitive functioning in the oldest-old [37, 38] and although olfactory impairment has been associated with incident dementia in a younger age group [39] , no studies were found studying this in the oldest-old.
Data about physical performance and activity have been collected in the Leiden 85-plus study and The 90+ Study. Good physical performance, measured with handgrip strength, 4 m walk or standing balance tests, was associated with better cognitive functioning and lower dementia incidence in the oldest-old but high physical activity did not seem to influence dementia incidence [16, 40, 41] .
With regard to genetics, the Apolipoprotein E (APOE) genotype, a major risk factor for AD in younger subjects, has been extensively studied in the oldest-old, with mixed results regarding the relation to cognition and dementia [42] [43] [44] [45] [46] . The Danish 1905 birth cohort, PLAD and Vantaa 85+ Study also studied a number of other genotypes in the oldest-old and found some additional protective and risk genotypes which are described in Table 2 .
Hallmarks of aging and cognition in the oldest-old
Hallmarks of aging [47] , such as inflammation and cellular senescence [48] , have been scarcely studied in relation to cognition in the oldest-old. The Leiden 85-plus Study and The 90+ Study related inflammation markers to cognition and dementia but showed mixed results [49] [50] [51] . In addition, telomere length measured in white blood cells were not associated with cognition, dementia prevalence or incident dementia [52] .
Markers of neurodegeneration and cognition in the oldest-old
Limited information is available about the relation of markers of neurodegeneration, such as amyloid β and tau measured in cerebrospinal fluid (CSF) and/or with a positron emission tomography (PET) scan with cognitive impairment in the oldest-old. Postmortem studies have Studies [6] a H85 Gothen-burg study [12] Leiden 85-plus Study [9] Newcastle 85+ Study [10] NonaSant-feliu study [8] Octabaix study [13] PLAD [15] The 90+ Study, USA [7] Umeå 85+ study [14] Vantaa 85+ Study [11] Cognitive reserve shown that the prevalence of amyloid aggregation increases with age in cognitively healthy subjects but decreases in the oldest-old subjects with dementia [1] . A similar trend can be seen with regard to amyloid β measured in CSF or on an amyloid PET scan [53, 54] . In subjects without dementia, greater amyloid load has been associated with poorer cognitive functioning and a higher rate of incident dementia, although the number of oldest-old subjects in these studies was limited [55] [56] [57] . There are a few studies that have related brain MRI measurements in the oldest-old to cognitive functioning. Less atrophy and fewer white matter hyperintensities were seen in subjects without dementia compared to subjects with dementia [58, 59] but white matter integrity was not related to cognition [60] . In younger subjects, neurophysiological measures on magnetoencephalography (MEG) have been related to dementia [61] but it is unknown whether this relationship persists in the oldest-old.
Aims and objectives of the EMIF-AD 90+ study
The EMIF-AD 90+ Study was set-up to investigate the protective factors for cognitive impairment in the oldest-old.
The study was part of the Innovative Medicine Initiative (IMI) European Medical Information Framework for AD (EMIF-AD) project (http://www.emif.eu/about/emif-ad) on diagnostic markers, prognostic markers, and protective factors for AD. The EMIF-AD 90+ study focuses on the extreme phenotype of the cognitively normal oldest-old. The primary objectives of the EMIF-AD 90+ study are:
i) To identify factors associated with resilience to cognitive impairment in the oldest-old. This paper describes the design and protocol of the study.
Methods
Study subjects
We aimed to include 80 cognitively normal subjects and 40 subjects with cognitive impairment, both aged 90 years and older. Inclusion criteria for cognitively normal subjects were a global Clinical Dementia Rating (CDR) score of 0 [62] and a score ≥ 26 points on the Mini--Mental State Examination (MMSE) [63] . Inclusion criteria for subjects with cognitive impairment were a diagnosis of amnestic MCI (aMCI) [64] or a diagnosis of probable or possible AD [65] by a neurologist, geriatrician, or general practitioner, a global CDR score ≥ 0.5 point (s) and a MMSE score of 20-28 points (inclusive). Exclusion criteria were the physical inability to undergo the procedures, visual or hearing impairment which made neuropsychological testing impossible, severe depression (Geriatric Depression Scale (GDS) score ≥ 11 points [66] ) and other comorbidities or medication that could impair cognition at the discretion of the investigator (e.g. stroke, epilepsy or use of lithium carbonate). During the inclusion period it turned out to be difficult to identify subjects of 90 years and older with aMCI or probable or possible AD; we therefore broadened the inclusion criteria in this group to subjects older than 85 years.
Subjects were recruited at two sites: the Amsterdam UMC, The Netherlands and The University of Manchester, United Kingdom. Cognitively normal subjects were recruited from general practitioners or via advertisements (Amsterdam) or from the Manchester and Newcastle Ageing Study (MNAS, Manchester). Subjects with cognitive impairment were only recruited in the Netherlands. 
Study design
The EMIF-AD 90+ Study is a case-control study in which we search for protective factors for cognitive impairment. Therefore, the cognitively normal subjects are described as cases and the subjects with cognitive impairment as controls.
Study procedures
The study consisted of two home visits and one or two visits at the hospital/clinical research facility (CRF). During the first home visit, in-and exclusion criteria (MMSE, CDR, impression of physical ability to undergo the procedures, hearing and visual abilities) were verified, in addition to collection of first study data (Table 3 , paragraphs 2.3.1, 2.3.2 and 2.3.4). The MMSE is a short cognitive screening test with a maximum score of 30 points [63] . The CDR is a scale for the severity of symptoms of dementia, which was assessed by interviews with the subject and, if available, study partner (somebody that is in regular contact with the subject) in combination with judgement by the researchers [62] . The second home visit consisted of a neuropsychological assessment performed by a neuropsychologist (paragraph 2.3.3). During the hospital/CRF visits several procedures were performed, which are listed in Table 3 and described in paragraphs 2.3.4. -2.3.10. These procedures provided information on i) potential protective factors (classified in six different domains), ii) hallmarks of aging, and iii) markers of neurodegeneration ( Fig. 1 and Table 3 ). For each domain, hallmark of aging or markers of neurodegeneration, we will test one or more parameters (Table 3) . In most cases, all procedures were performed within three months from start of the inclusion. Any differences in study procedures between Amsterdam and Manchester are explicitly stated in this paper.
Interview
Data about the medical and family history, medication use, education and intoxications (alcohol use and smoking) were collected through a structured interview, in combination with information provided by the study partner (if available), general practitioner and/or medical specialist.
Questionnaires
In Amsterdam, subjects were asked to complete six questionnaires. Activities of daily living (ADL) were evaluated by use of the Katz ADL [67] . Functional health and wellbeing were evaluated by the Short form-12 Health-related Quality of Life (SF-12 HRQoL) questionnaire [68] and by the Cognitive Complaints Index (CCI) [69] . Nutrition was evaluated by the Mini Nutritional Assessment (MNA-long version) [70] . Sleep disorders were evaluated by use of the Berlin Questionnaire which identifies the risk of sleep disordered breathing [71] . Cognitive activity during life, such as reading books and playing games, was assessed with the cognitive abilities questionnaire [72] . Subjects with cognitive impairment filled in the questionnaires together with a study partner. The GDS was filled in together with the researcher [66] . In Amsterdam, the study partner was asked to complete five questionnaires: the AD8 (an 8-question test for the study partner to assess mild dementia) [73] , the Amsterdam instrumental Activities of Daily Living (iADL) scale (a study partner based tool aimed at detecting iADL problems in early dementia) [74, 75] , the Neuropsychiatric Inventory Questionnaire (NPI-Q, to assess the severity of behavioral symptoms in the subject and the distress these symptoms cause in the study partner) [76] , the Mayo Sleep Questionnaire (MSQ, to screen for the presence of Rapid Eye Movement (REM) sleep disorders) [77] , and finally the CCI [69] .
In Manchester, subjects were asked to complete the SF-12 HRQoL questionnaire [68] , the Physical Activity Scale for the Elderly (PASE) [78] , the CCI [69] and the cognitive abilities questionnaire [72] . The study partner was asked to complete the AD8 [73] , the Functional Activities Questionnaire (FAQ) [79] and the CCI [69] .
Neuropsychological assessment
The neuropsychological assessment took approximately one and a half hours during which several cognitive domains were tested. Table 4 gives an overview of the different cognitive tests that were administered, which domain they examine and at which site they were performed.
Physical examination
In Amsterdam, data on waist and hip circumference (cm), and hand grip strength (kg), as well as a standard neurologic screening examination were recorded during the first home visit. Hand grip strength was measured to estimate muscle strength and was performed with a hand dynamometer (Jamar hand dynamometer; Sammons Preston, Inc., Bolingbrook, IL., USA) [80] . In addition, a 'Diagnostick' was used to determine whether the subject had atrial fibrillation by measuring one derivative of an electrocardiogram [81] . At the end of the first home visit, the subject was asked to wear an accelerometer (DynaPort MoveMonitor, McRoberts B.V., The Hague, The Netherlands) for seven days to measure physical activity and sleep quality.
During the hospital visit in Amsterdam, continuous blood pressure measurements were performed non-invasively using a digital photoplethysmogram on the right middle finger (Nexfin®, BMEYE, Amsterdam, The Netherlands), resulting in beat-to-beat BP data. The Short Physical Performance Battery (SPPB) included balance tests, a 4 m walk to measure walking speed and the chair stand test [82] . Body composition, including the Body Mass Index (BMI), was measured using a Bioelectrical Impedance Analysis (BIA; InBody 770; Biospace Co., Ltd., Seoul, Korea).
In Manchester, waist and hip circumference (cm), hand grip strength (kg), BMI, resting blood pressure, heart rate, ankle/brachial pressure index [83] and a 4 min walking test were recorded at the clinical research facility.
Sensory system
Measurements of the sensory system were only performed in Amsterdam. With regard to visual functioning, best corrected visual acuity was tested with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Intra-Ocular Pressure (IOP) and refraction data of all subjects were obtained, and all subjects underwent slit lamp examination and indirect fundoscopy. Pupils were dilated using tropicamide 0.5% and phenylephrine 5%. Peripapillary Retinal Nerve Fiber Layer (pRNFL) thickness and macular (layer) thickness were measured with Spectral Domain Optical Coherence Tomography (SD-OCT, Heidelberg Spectralis) using Heidelberg's build-in software [84] . With enhanced depth imaging, Fig. 1 Overview of the domains of interest in the EMIF-AD 90+ Study. Aβ Amyloid β, CSF cerebrospinal fluid, PET positron emission tomography the choroid was imaged and its thickness was (manually) measured. With fundus photography (Topcon TRC 50DX type IA), we acquired digital fundus images (50°). From these, seven Retinal Vascular Parameters (RVPs) were obtained using Singapore I Vessel Assessment (SIVA, version 3.0) [85] .
For the auditory function, we used the digits-in-noise (DIN) test [86] . The DIN test is a speech-in-noise test using digit triplets as speech material. The digit triplets are presented against a constant level of stationary background noise. The test uses an adaptive procedure to determine the signal-to-noise ratio at which a listener understands 50% of the digit triplets correctly (i.e. the speech reception threshold (SRT) in noise). Olfactory function was measured using "Sniffin' Sticks" (Burghart, Wedel, Germany). The test consists of pen-like odor dispensing devices with odors that are considered to be familiar. The smell test in the present study contained the odor identification part of the test [87] .
Blood collection and skin biopsy
In both centers, blood samples were collected according to the biobanking pre-analytical Standard Operating Procedures (SOPs) of the Biomarkers for Alzheimer's disease and Parkinson's disease (BIOMARKAPD) project [88] . Blood samples were collected for DNA and RNA analysis, inflammation markers, proteomics, neurodegenerative markers (amyloid β, tau, neurofilament light), routine blood analysis (i.e. lipids and glucose), vitamin status (B12 and folic acid) and, in Amsterdam only, for Peripheral Blood Mononuclear Cells (PBMCs). Planned DNA analysis includes Single Nucleotide Polymorphisms (SNP) analysis of known genetic risk factors for AD or amyloid pathology [89] [90] [91] [92] . DNA and RNA isolation will The subject will be asked to draw a clock showing the time "ten after eleven". In total 14 points can be scored based on the presence and sequencing of the numbers and the positioning of the two hands be performed by EMIF-AD partners. Remaining samples will be stored for future biomarker identification and validation studies.
In Amsterdam, four millimeter skin biopsies were taken from the inner upper medial arm and will be stained for senescence markers p16, p53 and telomere associated foci.
Cerebrospinal fluid collection
In Amsterdam, up to 20 mL CSF was obtained by lumbar puncture in Sarstedt polypropylene syringes using a Spinocan 25 Gauge needle in one of the intervertebral spaces between L3 and S1. A half mL CSF was immediately processed for leukocyte count, erythrocyte count, glucose, and total protein. The remaining CSF was mixed and centrifuged at 1300-2000 × g at 4°C for ten minutes. Supernatants were stored in aliquots of 0.25-0.5 mL and frozen within two hours at − 80°C and stored for future biomarker discovery studies. The processing and storing of CSF was performed according to the BIOMARKAPD SOP [88] . Amyloid β 1-42, total tau and phosphorylated tau 181 will be analyzed in a single batch. Remaining samples will be stored for future biomarker identification and validation studies.
Ultrasound carotid artery
At both sites, a duplex ultrasound scan of the carotid artery was performed. In Amsterdam, the right carotid artery was scanned to assess intima media thickness and distension using ArtLab software [93, 94] . In Manchester, left and right carotid arteries were scanned to determine velocity, vessel thickness, stenosis and plaques, rated according to the North American Symptomatic Carotid Endarterectomy Trial guidelines [95] .
Brain MRI scan
Subjects underwent locally optimized brain MRI protocols including 3D-T1, fluid attenuated inversion recovery (FLAIR), susceptibility weighted imaging (SWI), diffusion tensor imaging (DTI) and resting state functional MRI (rs-fMRI). MRI scans were performed on Philips 3 T Achieva scanners. Additionally, in Manchester regional cerebral blood flow was measured by arterial spin labelling [96] , but no DTI scan was acquired in Manchester. In Amsterdam, if a subject could not undergo the MRI scan, we considered a CT scan (Philips Ingenuity TF or Gemini TF camera). Scans will be analyzed locally and centrally by EMIF-AD partners using the Neugrid infrastructure if applicable (see Additional file 1).
Amyloid PET scan Cs point source were acquired for subsequent attenuation and scatter correction.
All [
18 F] flutemetamol scans were read visually as positive or negative. Additionally, we determined time activity curves for each region of interest with cerebellum grey matter as input function [97] . The dynamic data were analyzed on a voxel-by-voxel level using the Simplified Reference Tissue Model 2 (SRTM2) [98, 99] . Finally, we investigated tracer uptake by using a simplified method: the standardized uptake value ratio (SUVr, target to grey matter cerebellum SUV over 90-110 min pi) [100] . Variability in acquisition of amyloid PET scans were reduced by harmonizing acquisition protocols and will be reduced by adding it to the analyses as a covariate.
Neurophysiology
In Amsterdam, MEG was performed using a 306 channel whole-head system (Elekta Neuromag Oy, Helsinki, Finland). Eyes-closed and eyes-open resting-state MEG data were recorded with subjects in supine position inside a magnetically shielded room. We will use transformed time series [101] to extract spectral properties (relative band power and peak frequency) [102] , and estimates of functional connectivity between brain regions, and metrics that characterize the topology of the functional brain networks [103, 104] . These analyses will be applied using Elekta's beamformer software, and both in-house developed Matlab tools and BrainWave software (http://home.kpn.nl/stam7883/brainwave.html).
Planned statistical analyses
For each parameter listed in Table 3 , we will test with logistic regression models whether it is associated with resilience to cognitive impairment. In addition, linear regression models will be used to associate the same parameters with cognitive functioning in the total sample. Potential additional analyses include the identification of protective factors for abnormal AD biomarkers in the subsample of cognitively normal subjects and the identification of protective factors for cognitive impairment in subjects with a high risk, for example APOE ε4 carriers.
Discussion
We described the design of the EMIF-AD 90+ Study that aims to unravel the factors associated with resilience to cognitive impairment in the oldest-old. An important additional value of the EMIF-AD 90+ Study compared to the previous studies is the extensive phenotyping of subjects, which includes data about cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity and genetic risk factors. Furthermore, the EMIF-AD 90+ Study is one of the first studies that collects a broad range of markers of neurodegeneration in the oldest-old, including an amyloid PET scan, amyloid β and tau measured in CSF and blood and neurophysiological measures.
The EMIF-AD 90+ is the first study worldwide that combines data regarding the hallmarks of aging with markers of neurodegeneration. The process of aging and the incidence of aMCI and possible or probable AD are very much interrelated. Our study allows to test hypotheses such as that common risk factors and pathways drive both the aging process and development of cognitive impairment or AD. Another strength of the EMIF-AD 90+ study is that we use objective measures wherever possible, instead of using questionnaires. For example, physical activity and sleep quality were measured with an accelerometer in Amsterdam.
To conclude, the results of the EMIF-AD 90+ Study will provide an important contribution to the existing literature in many different ways. It will extend our knowledge on protective factors for cognitive impairment in the oldest-old and will determine how hallmarks of aging and markers of neurodegeneration relate to cognitive impairment in this specific age group.
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